Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg
2013-05-23 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 23 May 2013 - Novo Nordisk today announced the headline results from a 56-week double-blind phase 3a clinical trial investigating the potential of liraglutide to induce and maintain weight loss in people without diabetes who are obese or overweight with comorbidities such as prediabetes, hypertension and dyslipidaemia. This is the third phase 3a trial to be completed as part of SCALE(TM), the clinical development programme for liraglutide 3 mg as an obesity treatment. Further information Media: Daniel Vámosi Martinussen +45 3079 1879 [email protected] Ken Inchausti (US) +1 609 240 2919 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 39 2013
The release as fetched from its publisher. novonordisk.com ↗